TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: “This agreement represents a significant milestone for EpiCept and welcome news for patients suffering from AML in Europe, who will now be able to readily access this life saving medicine once launched” EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today that it has entered into an exclusive commercialization agreement for Ceplene® (histamine dihydrochloride) with Meda AB, (OMX Nordic Exchange: MEDA-A-ST) a leading international specialty pharmaceutical company based in Stockholm. Ceplene is EpiCept’s novel therapy approved in the European Union with orphan drug status for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission.
